RESEARCH-BASED
pharmaceutical giant
GlaxoSmithKline
(GSK) has confirmed
it will prioritise
whooping cough vaccine availability
for those most at risk of the disease
and will ensure uninterrupted
supply of Boostrix to all Australian
State, Territory and Federal
Government vaccination programs
where Boostrix is the vaccine of
choice.
Boostrix is a combined diphtheriatetanus-
acellular pertussis
(whooping cough) (dTpa) vaccine.
For more information, the
company has a med info line on
1800 033 109.The above article was sent to subscribers in Pharmacy Daily's issue from 19 Jan 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Jan 16
PEAK industry bodies have welcomed Labor Government’s 2024-25 Commonwealth Budget handed down last night, which introduced financial relief measures aimed at assisting patients and community pharmacies.
AFFORDABLE healthcare for more Australians was highlighted in yesterday’s Federal Budget, with funds allocated to services for Aboriginal and Torres Strait Islander people.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.